1403676-70-9

Basic information

• Product Name: tert-butyl 4-(4-((2-fluoro-4-(methylsulfonyl)phenoxy)methyl)-2-hydroxycyclohexyl)piperazine-1-carboxylate
• Synonyms: tert-butyl 4-(4-((2-fluoro-4-(methylsulfonyl)phenoxy)methyl)-2-hydroxycyclohexyl)piperazine-1-carboxylate
• CAS NO: 1403676-70-9
• Molecular Weight: 486.605
• Mol File: 1403676-70-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-(4-((2-fluoro-4-(methylsulfonyl)phenoxy)methyl)-2-hydroxycyclohexyl)piperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(4-((2-fluoro-4-(methylsulfonyl)phenoxy)methyl)-2-hydroxycyclohexyl)piperazine-1-carboxylate(1403676-70-9)
• EPA Substance Registry System: tert-butyl 4-(4-((2-fluoro-4-(methylsulfonyl)phenoxy)methyl)-2-hydroxycyclohexyl)piperazine-1-carboxylate(1403676-70-9)

Safety Data

• Hazardous Substances Data: 1403676-70-9(Hazardous Substances Data)

Upstream product

• 1489-97-0 ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 
• 23521-81-5 (1,4-dioxaspiro[4.5]dec-8-yl)methanol 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 147767-55-3 (1,4-dioxaspiro[4.5]dec-8-yl)methyl methanesulfonic acid 
• 1403676-74-3 4-((2-fluoro-4-(methylsulfonyl)phenoxy)methyl)cyclohexanone 
• 1403676-73-2 8-((2-fluoro-4-(methylsulfonyl)phenoxy)methyl)-1,4-dioxaspiro[4.5]decane 

Downstream Products

• 1403676-95-8 tert-butyl 4-(4-((2-fluoro-4-(methylsulfonyl)phenoxy)methyl)-2-oxocyclohexyl)piperazine-1-carboxylate 

Relevant articles and documents

MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO

The present invention relates to compounds of Formula I and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of, for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.